Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

被引：0
|
作者：
Zhu, Jun [1 ]
Yeoh, Ee-Min [2 ]
Maeda, Yoshinobu [3 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma, Beijing, Peoples R China
[2] Mundipharma, Singapore, Singapore
[3] Okayama Univ, Dept Hematol & Oncol, Okayama, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124080
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5290
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis
    Zhu, Jun
    Yeoh, Ee Min
    Maeda, Yoshinobu
    Tobinai, Kensei
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2145 - 2152
  • [2] A Meta-Analysis of Pivotal Pralatrexate Studies in Relapsed/Refractory Mature T-Cell Lymphoma (r/r TCL)
    O'Connor, Owen A.
    Ko, Bor-Sheng
    Wang, Ming-Chung
    Maruyama, Dai
    Song, Yuqin
    Yeoh, Ee-Min
    Tobinai, Kensei
    [J]. BLOOD, 2021, 138
  • [3] Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma
    O'Connor, Owen A.
    Ko, Bor-Sheng
    Wang, Ming-Chung
    Maruyama, Dai
    Song, Yuqin
    Yeoh, Ee-Min
    Manamley, Nick
    Tobinai, Kensei
    [J]. BLOOD ADVANCES, 2024, 8 (11) : 2601 - 2611
  • [4] Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
    Pro, Barbara
    Horwitz, Steven M.
    Prince, H. Miles
    Foss, Francine M.
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Morschhauser, Franck
    Wilhelm, Martin
    Pinter-Brown, Lauren
    Iyer, Swaminathan Padmanabhan
    Malignancies, Hematological
    Shustov, Andrei R.
    Wolfson, Julie
    Balser, Barbara E.
    Coiffier, Bertrand
    [J]. BLOOD, 2014, 124 (21)
  • [5] Responses to romidepsin by line of therapy in patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL).
    Foss, Francine M.
    Pro, Barbara
    Prince, H. Miles
    Sokol, Lubomir
    Greenwood, Matthew
    Caballero, Dolores
    Horwitz, Steven M.
    Coiffier, Bertrand
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
    Sawas, Ahmed
    Ma, Helen
    Shustov, Andrei
    Hsu, Pamela
    Bhat, Gajanan
    Acosta, Mark
    Horwitz, Steven M.
    O'Connor, Owen A.
    [J]. BLOOD, 2019, 134
  • [7] A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)
    Chavez, Julio C.
    Foss, Francine M.
    William, Basem M.
    Brammer, Jonathan E.
    Smith, Sonali M.
    Prica, Anca
    Zain, Jasmine M.
    Tuscano, Joseph M.
    Glenn, Martha
    Mehta-Shah, Neha
    Wang, Ben X.
    Zantinge, Stephanie
    Wang, Lisa
    Zhang, Ling
    Boutrin, Anmarie
    Zhao, Weiguang
    Cheng, Lily
    Standifer, Nathan
    Carlesso, Gianluca
    Moscow, Jeffrey
    Siu, Lillian
    [J]. BLOOD, 2020, 136
  • [8] Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate
    O'Connor, Owen A.
    Marchi, Enrica
    Volinn, Weining
    Kim, Won Seog
    [J]. BLOOD, 2016, 128 (22)
  • [9] TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy
    Viviani, Simonetta
    Spina, Francesco
    Mazzocchi, Arabella
    Galbiati, Maria
    Crippa, Flavio
    Farina, Lucia
    Guidetti, Anna
    Di Nicola, Massimo
    Devizzi, Liliana Franca
    Matteucci, Paola
    Magni, Michele
    Dodero, Anna
    Gianni, Alessandro M.
    Corradini, Paolo
    [J]. BLOOD, 2016, 128 (22)
  • [10] Analysis of Patterns of Failure and the Role of Bridging Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Treated with CAR T-Cell Therapy
    Ravella, R.
    Zhang-Velten, E. R.
    Awan, F.
    Rizvi, S.
    Shah, J. L.
    Desai, N. B.
    Geethakumari, P. Ramakrishnan
    Kumar, K. A., Jr.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E305 - E306
12345